Answer
Ketoconazole strongly inhibits CYP3A and can increase cabazitaxel exposure, so concurrent use should be avoided; repeated ketoconazole at 400 mg once daily reduced cabazitaxel clearance by 20% and increased exposure (AUC) by 25%.
Sources for this answer
- Cabazitaxel 60 mg Concentrate and Solvent For Solution For InfusionDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 5Document updated
Sources checked